Latest Menorrhagia Stories

BEDFORD, Mass., July 12 /PRNewswire-FirstCall/ -- Hologic, Inc. (Nasdaq: HOLX) today announced that Glenn Muir, Chief Financial Officer, will present at the Canaccord Genuity 30th Annual Growth Conference 2010 on Wednesday, August 11, 2010 at 1:00 p.m. (Eastern). Interested parties are invited to listen to the live audio webcast of Hologic's investor presentation on the investor section of the company's website at www.hologic.com/investor-overview. An archive of the presentation will be...

PARSIPPANY, N.J., June 21 /PRNewswire/ -- Ferring Pharmaceuticals Inc. announced today the U.S. commercial availability of LYSTEDA(TM) (tranexamic acid) tablets, the only non-hormonal and non-surgical therapy indicated specifically for the treatment of women with cyclic heavy menstrual bleeding (HMB). In clinical studies, LYSTEDA significantly reduced menstrual blood loss (MBL) over three and six cycles of use with the reduction seen as early as the first cycle of use. It also...

ABBOTT PARK, Ill. and SAN DIEGO, June 16 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) and Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that they have entered into a collaboration agreement to develop and commercialize elagolix for the treatment of endometriosis-related pain. Elagolix is a novel, first-in-class oral gonadotropin-releasing hormone (GnRH) antagonist, which has recently completed a phase IIb study in endometriosis. In addition to endometriosis, elagolix will be...

WAYNE, N.J., June 15 /PRNewswire/ -- Today, Bayer HealthCare Pharmaceuticals Inc. and Bayer Schering Pharma AG sued Teva Pharmaceuticals USA, Inc., Barr Pharmaceuticals LLC, and Barr Laboratories, Inc. in the Northern District of Illinois (Chicago) for false advertising and patent infringement in connection with Teva's generic oral contraceptive, Gianvi(TM). Teva's product is sold as a generic version of Bayer HealthCare's leading oral contraceptive YAZ®. YAZ® tablets contain an...

SAN DIEGO, May 24 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced statistically significant and clinically meaningful top-line efficacy results from its Phase II Daisy PETAL study (901 study) using its proprietary, orally-active nonpeptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix, in patients with endometriosis. "The Daisy PETAL study was successful, all primary and secondary efficacy endpoints were met, and provided exactly...

SAN FRANCISCO, May 19 /PRNewswire/ -- Five presentations reporting the results of two placebo-controlled clinical trials evaluating Ferring Pharmaceuticals' LYSTEDA(TM) (tranexamic acid) tablets, a novel, first-in-class, non-hormonal therapy indicated for treatment of women with cyclic heavy menstrual bleeding (HMB), were presented at The American College of Obstetricians and Gynecologists 58th Annual Clinical Meeting in San Francisco, May 15-19, 2010. It is estimated that up to 22 million...

NATICK, Mass., May 18 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced U.S. Food and Drug Administration (FDA) approval of its Genesys HTA(TM) System for the treatment of menorrhagia. The Genesys HTA System is a next-generation endometrial ablation system designed to ablate the endometrial lining of the uterus in premenopausal women with menorrhagia. Menorrhagia is abnormally heavy and prolonged menstrual bleeding. An estimated 10 million women in the...

BEDFORD, Mass., May 11 /PRNewswire-FirstCall/ -- Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, announced today the availability of its next generation NovaSure(®) system -- a 90-second, minimally-invasive, outpatient treatment for women suffering from excessive menstrual bleeding. The next generation...

NEWPORT, Ky., May 10 /PRNewswire/ -- Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical company, today announced that it has tightly focused the strategic direction for the company on the pain management market. The company plans to leverage its core expertise in the prescription pain category by developing a range of products that address both the acute and chronic pain prescription segments as well as the over-the-counter pain market. Xanodyne has nearly a...

Scientists described yesterday the discovery of a new drug, which is currently in Phase II clinical trials, designed to specifically target the root cause of painful menstrual cramps, not just the symptoms. The condition, called dysmenorrhea, is the leading cause of absenteeism from school and work among women in their teens and 20s. The scientists described the study at the American Chemical Society (ACS) 239th National Meeting, being held this week."We hope that the drug will provide a...